Apex Biotechnology

Apex Biotechnology EBIT per Share

The EBIT per Share of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 1.41 TWD. In the previous year, EBIT per Share was 1.28 TWD — a change of 9.59% (higher).

EBIT per Share

1.41TWD

YoY

9.59%

Last updated:

EBIT per Share of Apex Biotechnology is 2025 1.41 TWD. EBIT per Share of Apex Biotechnology was 2024 1.28 TWD. It decreases by 9.59% higher compared to the previous year.

The Apex Biotechnology EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
1.77 TWD
Jan 1, 2020
1.20 TWD
Jan 1, 2021
2.41 TWD
Jan 1, 2022
2.05 TWD
Jan 1, 2023
1.42 TWD
Jan 1, 2024
1.28 TWD
Jan 1, 2025
1.41 TWD
Jan 1, 2026 (e)
8.38 TWD
The Apex Biotechnology EBIT per Share history
YEAREBIT per ShareYoY
est8.38TWD+495.99%
1.41TWD+9.59%
1.28TWD-9.56%
1.42TWD-30.86%
2.05TWD-14.88%
2.41TWD+100.84%
1.20TWD-32.18%
1.77TWD-22.83%
2.29TWD+43.04%
1.60TWD-18.21%
1.96TWD-36.10%
3.07TWD+5.06%
2.92TWD-16.95%
3.51TWD-43.23%
6.19TWD+6.37%
5.82TWD-2.85%
5.99TWD+33.80%
4.48TWD+24.56%
3.59TWD-20.28%
4.51TWD+40.65%
3.21TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

EBIT per Share of Apex Biotechnology is 1.41 TWD in 2025.

EBIT per Share of Apex Biotechnology changed from 1.28 TWD to 1.41 TWD, representing a 9.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Apex Biotechnology

All Key Metrics — Apex Biotechnology